text:
Congenital adrenal hyperplasia
From Wikipedia, the free encyclopedia
Jump to: navigation, search
"Adrenal hyperplasia" redirects here. You may also be interested in Primary aldosteronism or Cushing's syndrome.
Congenital adrenal hyperplasia
Classification and external resources
Specialty
Pediatrics, medical genetics
ICD-10
E25.0
ICD-9-CM
255.2
OMIM
201910 201710 202110 201810 202010
DiseasesDB
1854 1832
MedlinePlus
000411
eMedicine
ped/48
MeSH
D000312
Orphanet
418
[edit on Wikidata]
Congenital adrenal hyperplasia (CAH) are any of several autosomal recessive diseases resulting from mutations of genes for enzymes mediating the biochemical steps of production of mineralocorticoids, glucocorticoids or sex steroids from cholesterol by the adrenal glands (steroidogenesis).[1]
Most of these conditions involve excessive or deficient production of sex steroids and can alter development of primary or secondary sex characteristics in some affected infants, children, or adults.[2]
Contents
[hide]
1 Signs and symptoms
2 Genetics
2.1 Expression
3 Diagnosis
3.1 Clinical evaluation
3.2 Laboratory studies
3.3 Classification
4 Screening
5 Treatment
6 Epidemiology
7 History
7.1 Before 20th century
7.2 20th and 21st century
8 See also
9 References
10 Further reading
11 External links
Signs and symptoms[edit]
The symptoms of CAH vary depending upon the form of CAH and the sex of the patient. Symptoms can include:
Due to inadequate mineralocorticoids:
vomiting due to salt-wasting leading to dehydration and death
Due to excess androgens:
functional and average sized penis in cases involving extreme virilization (but no sperm)
ambiguous genitalia, in some females, such that it can be initially difficult to identify external genitalia as "male" or "female".
early pubic hair and rapid growth in childhood
precocious puberty or failure of puberty to occur (sexual infantilism: absent or delayed puberty)
excessive facial hair, virilization, and/or menstrual irregularity in adolescence
infertility due to anovulation
clitoromegaly, enlarged clitoris and shallow vagina[3]
Due to insufficient androgens and estrogens:[citation needed]
Undervirilization in XY males, which can result in apparently female external genitalia
In females, hypogonadism can cause sexual infantilism or abnormal pubertal development, infertility, and other reproductive system abnormalities
Genetics[edit]
Each form of CAH is associated with a specific defective gene. The most common type (95% of cases) involves the gene for 21-hydroxylase, which is found on 6p21.3 as part of the HLA complex. 21-hydroxylase deficiency results from a unique mutation with two highly homologous near-copies in series consisting of an active gene (CYP21A) and an inactive pseudogene (CYP21P). Mutant alleles result from recombination between the active and pseudo genes (gene conversion).[4]
Expression[edit]
Further variability is introduced by the degree of enzyme inefficiency produced by the specific alleles each patient has. Some alleles result in more severe degrees of enzyme inefficiency. In general, severe degrees of inefficiency produce changes in the fetus and problems in prenatal or perinatal life. Milder degrees of inefficiency are usually associated with excessive or deficient sex hormone effects in childhood or adolescence, while the mildest forms of CAH interfere with ovulation and fertility in adults.
Diagnosis[edit]
This section needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (October 2015) (Learn how and when to remove this template message)
Clinical evaluation[edit]
Female infants with classic CAH have ambiguous genitalia due to exposure to high concentrations of androgens in utero. CAH due to 21-hydroxylase deficiency is the most common cause of ambiguous genitalia in genotypically normal female infants (46XX). Less severely affected females may present with early pubarche. Young women may present with symptoms of polycystic ovarian syndrome (oligomenorrhea, polycystic ovaries, hirsutism).
Males with classic CAH generally have no signs of CAH at birth. Some may present with hyperpigmentation, due to co-secretion with melanocyte-stimulating hormone (MSH), and possible penile enlargement. Age of diagnosis of males with CAH varies and depends on the severity of aldosterone deficiency. Boys with salt-wasting disease present early with symptoms of hyponatremia and hypovolemia. Boys with non-salt-wasting disease present later with signs of virilization.[4]
In rarer forms of CAH, males are under-masculinized[citation needed] and females generally have no signs or symptoms at birth.
Laboratory studies[edit]
Genetic analysis can be helpful to confirm a diagnosis of CAH but it is not necessary if classic clinical and laboratory findings are present.
In classic 21-hydroxylase deficiency, laboratory studies will show:
hypoglycemia (due to hypocortisolism)
hyponatremia (due to hypoaldosteronism)
hyperkalemia (due to hypoaldosteronism)
elevated 17α-hydroxyprogesterone
Classic 21-hydroxylase deficiency typically causes 17α-hydroxyprogesterone blood levels >242 nmol/L. (For comparison, a full-term infant at three days of age should have <3 nmol/L. Many neonatal screening programs have specific reference ranges by weight and gestational age because high levels may be seen in premature infants without CAH.) Salt-wasting patients tend to have higher 17α-hydroxyprogesterone levels than non-salt-wasting patients. In mild cases, 17α-hydroxyprogesterone may not be elevated in a particular random blood sample, but it will rise during a corticotropin stimulation test.
Classification[edit]
Cortisol is an adrenal steroid hormone that is required for normal endocrine function. Production begins in the second month of fetal life. Poor cortisol production is a hallmark of most forms of CAH. Inefficient cortisol production results in rising levels of ACTH, because cortisol feeds back to inhibit ACTH production, so loss of cortisol results in increased ACTH. This increased ACTH stimulation induces overgrowth (hyperplasia) and overactivity of the steroid-producing cells of the adrenal cortex. The defects causing adrenal hyperplasia are congenital (i.e. present at birth).
Steroidogenesis. The enzymes affected in CAH are represented by one red and four green bars on the top half of the diagram (for example, "21α-hydroxylase" is visible near the top center. "17α-hydroxylase" and "17,20 lyase" are carried out by a single enzyme).[5] Depending upon which enzyme is unavailable, there is a reduced production of androgens (lower left) or mineralocorticoids (upper right). This in turn can lead to increased production of other molecules, due to a buildup of precursors.
Cortisol deficiency in CAH is usually partial, and not the most serious problem for an affected person. Synthesis of cortisol shares steps with synthesis of mineralocorticoids such as aldosterone, androgens such as testosterone, and estrogens such as estradiol. The resulting excessive or deficient production of these three classes of hormones produce the most important problems for people with CAH. Specific enzyme inefficiencies are associated with characteristic patterns of over- or underproduction of mineralocorticoids or sex steroids.
Common medical term
%
OMIM
Enzyme(s)
Locus
Substrate(s)
Product(s)
Mineralocorticoids
Androgens
21-hydroxylase CAH 90-95% 201910 P450c21 6p21.3 17OH-progesterone→
progesterone→ 11-deoxycortisol
DOC ↓ ↑
11β-hydroxylase CAH 5% 202010 P450c11β 8q21-22 11-deoxycortisol→
DOC→ cortisol
corticosterone ↑ ↑
3β-HSD CAH very rare 201810 3βHSD II 1p13 pregnenolone→
17OH-pregnenolone→
DHEA→ progesterone
17OH-progesterone
androstenedione ↓ ↓
17α-hydroxylase CAH very rare 202110 P450c17 10q24.3 pregnenolone→
progesterone→
17OH-pregnenolone→ 17OH-pregnenolone
17OH-progesterone
DHEA ↑ ↓
lipoid CAH
(20,22-desmolase) very rare 201710 StAR
P450scc 8p11.2
15q23-q24 transport of cholesterol
cholesterol→ into mitochondria
pregnenolone ↓ ↓
Since the 1960s most endocrinologists have referred to the forms of CAH by the traditional names in the left column, which generally correspond to the deficient enzyme activity. As exact structures and genes for the enzymes were identified in the 1980s, most of the enzymes were found to be cytochrome P450 oxidases and were renamed to reflect this. In some cases, more than one enzyme was found to participate in a reaction, and in other cases a single enzyme mediated in more than one reaction. There was also variation in different tissues and mammalian species.
In all its forms, congenital adrenal hyperplasia due to 21-hydroxylase deficiency accounts for about 95% of diagnosed cases of CAH. Unless another specific enzyme is mentioned, "CAH" in nearly all contexts refers to 21-hydroxylase deficiency. (The terms "salt-wasting CAH", and "simple virilizing CAH" usually refer to subtypes of this condition.) CAH due to deficiencies of enzymes other than 21-hydroxylase present many of the same management challenges as 21-hydroxylase deficiency, but some involve mineralocorticoid excess or sex steroid deficiency.
Screening[edit]
Currently, in the United States and over 40 other countries, every child born is screened for 21-hydroxylaase CAH at birth. This test will detect elevated levels of 17-hydroxy-progesterone (17-OHP). Detecting high levels of 17-OHP enables early detection of CAH. Newborns detected early enough can be placed on medication and live a relatively normal life.
The screening process, however, is characterized by a high false positive rate. In one study,[6] CAH screening had the lowest positive predictive value (111 true-positive cases among 20,647 abnormal screening results in a 2-year period, or 0.53%, compared with 6.36% for biotinidase deficiency, 1.84% for congenital hypo-thyroidism, 0.56% for classic galactosemia, and 2.9% for phenylketonuria). According to this estimate, 200 unaffected newborns required clinical and laboratory follow-up for every true case of CAH.
Treatment[edit]
Treatment of all forms of CAH may include any of:
supplying enough glucocorticoid to reduce hyperplasia and overproduction of androgens or mineralocorticoids
providing replacement mineralocorticoid and extra salt if the person is deficient
providing replacement testosterone or estrogen at puberty if the person is deficient
additional treatments to optimize growth by delaying puberty or delaying bone maturation
All of these management issues are discussed in more detail in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Dexamethasone is used as an off-label early pre-natal treatment for the symptoms of CAH in female fetuses, but it does not treat the underlying congenital disorder. A 2007 Swedish clinical trial found that treatment may cause cognitive and behavioural defects, but the small number of test subjects means the study cannot be considered definitive. A 2012 American study found no negative short term outcomes, but "lower cognitive processing in CAH girls and women with long-term DEX exposure."[7] Administration of pre-natal dexamethasone has been the subject of controversy over issues of informed consent and because treatment must predate a clinical diagnosis of CAH in the female fetus,[8] especially because in utero dexamethasone may cause metabolic problems that are not evident until later in life; Swedish clinics ceased recruitment for research in 2010.[9]
The treatment has also raised concerns in LGBT and bioethics communities following publication of an essay posted to the forum of the Hastings Center, and research in the Journal of Bioethical Inquiry, which found that pre-natal treatment of female fetuses was suggested to prevent those fetuses from becoming lesbians after birth, may make them more likely to engage in "traditionally" female-identified behaviour and careers, and more interested in bearing and raising children. Citing a known attempt by a man using his knowledge of the fraternal birth order effect to avoid having a homosexual son by using a surrogate, the essayists (Professor Alice Dreger of Northwestern University's Feinberg School of Medicine, Professor Ellen Feder of American University and attorney Anne Tamar-Mattis) suggest that pre-natal "dex" treatments constitute the first known attempt to use in utero protocols to reduce the incidence of homosexuality and bisexuality in humans.[10][11] Research on the use of prenatal hormone treatments to prevent homosexuality stretches back to the early 1990s or earlier.[12]
Since CAH is a recessive gene, both the mother and father must be recessive carriers of CAH for a child to have CAH. Due to advances in modern medicine, those couples with the recessive CAH genes have an option to prevent CAH in their offspring through preimplantation genetic diagnosis (PGD). In PGD, the egg is fertilized outside the women's body in a petri dish (IVF). On the 3rd day, when the embryo has developed from one cell to about 4 to 6 cells, one of those cells is removed from the embryo without harming the embryo. The embryo continues to grow until day 5 when it is either frozen or implanted into the mother. Meanwhile, the removed cell is analyzed to determine if the embryo has CAH. If the embryo is determined to have CAH, the parents may make a decision as to whether they wish to have it implanted in the mother or not.[citation needed]
Meta-analysis of the studies supporting the use of dexamethasone on CAH at-risk fetuses found "less than one half of one percent of published 'studies' of this intervention were regarded as being of high enough quality to provide meaningful data for a meta-analysis. Even these four studies were of low quality" ... "in ways so slipshod as to breach professional standards of medical ethics"[13] and "there were no data on long-term follow-up of physical and metabolic outcomes in children exposed to dexamethasone".[14]
Epidemiology[edit]
The incidence varies geographically. In the United States, congenital adrenal hyperplasia is particularly common in Native Americans and Yupik Eskimos (incidence 1⁄280). Among American Caucasians, the incidence is approximately 1⁄15,000).[4]
History[edit]
Before 20th century[edit]
An Italian anatomist, Luigi De Crecchio (1832-1894) provided the earliest known description of a case of probable CAH.
I propose in this narrative that it is sometimes extremely difficult and even impossible to determine sex during life. In one of the anatomical theaters of the hospital..., there arrived toward the end of January a cadaver which in life was the body of a certain Joseph Marzo... The general physiognomy was decidedly male in all respects. There were no feminine curves to the body. There was a heavy beard. There was some delicacy of structure with muscles that were not very well developed... The distribution of pubic hair was typical of the male. Perhaps the lower extremities were somewhat delicate, resembling the female, and were covered with hair... The penis was curved posteriorly and measured 6 cm, or with stretching, 10 cm. The corona was 3 cm long and 8 cm in circumference. There was an ample prepuce. There was a first grade hypospadias... There were two folds of skin coming from the top of the penis and encircling it on either side. These were somewhat loose and resembled labia majora.
De Crecchio then described the internal organs, which included a normal vagina, uterus, tubes, and ovaries.
It was of the greatest importance to determine the habits, tendencies, passions, and general character of this individual... I was determined to get as complete a story as possible, determined to get at the base of the facts and to avoid undue exaggeration which was rampant in the conversation of many of the people present at the time of the dissection.
He interviewed many people and satisfied himself that Joseph Marzo "conducted himself within the sexual area exclusively as a male", even to the point of contracting the "French disease" on two occasions. The cause of death was another in a series of episodes of vomiting and diarrhea.[15]
This account was translated by Alfred Bongiovanni from De Crecchio ("Sopra un caso di apparenzi virili in una donna". Morgagni 7:154–188, 1865) in 1963 for an article in The New England Journal of Medicine.
20th and 21st century[edit]
The association of excessive sex steroid effects with diseases of the adrenal cortex have been recognized for over a century. The term adrenogenital syndrome was applied to both sex-steroid producing tumors and severe forms of CAH for much of the 20th century, before some of the forms of CAH were understood. Congenital adrenal hyperplasia, which also dates to the first half of the century, has become the preferred term to reduce ambiguity and to emphasize the underlying pathophysiology of the disorders.
Much of our modern understanding and treatment of CAH comes from research conducted at Johns Hopkins Medical School in Baltimore in the middle of the 20th century. Lawson Wilkins, "founder" of pediatric endocrinology, worked out the apparently paradoxical pathophysiology: that hyperplasia and overproduction of adrenal androgens resulted from impaired capacity for making cortisol. He reported use of adrenal cortical extracts to treat children with CAH in 1950. Genital reconstructive surgery was also pioneered at Hopkins. After application of karyotyping to CAH and other intersex disorders in the 1950s, John Money, JL Hampson, and JG Hampson persuaded both the scientific community and the public that sex assignment should not be based on any single biological criterion, and gender identity was largely learned and has no simple relationship with chromosomes or hormones. See Intersex for a fuller history, including recent controversies over reconstructive surgery.
Hydrocortisone, fludrocortisone, and prednisone were available by the late 1950s. By 1980 all of the relevant steroids could be measured in blood by reference laboratories for patient care. By 1990 nearly all specific genes and enzymes had been identified.
However, the last decade has seen a number of new developments, discussed more extensively in congenital adrenal hyperplasia due to 21-hydroxylase deficiency:
debate over the value of genital reconstructive surgery and changing standards
debate over sex assignment of severely virilized XX infants
new treatments to improve height outcomes
newborn screening programs to detect CAH at birth
increasing attempts to treat CAH before birth
See also[edit]
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency
Congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency
Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency
Disorders of sex development
Inborn errors of steroid metabolism
References[edit]
Jump up ^ David A. Warrell (2005). Oxford textbook of medicine: Sections 18-33. Oxford University Press. pp. 261–. ISBN 978-0-19-856978-7. Retrieved 14 June 2010.
Jump up ^ Aubrey Milunsky; Jeff Milunsky (29 January 2010). Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment. John Wiley and Sons. pp. 600–. ISBN 978-1-4051-9087-9. Retrieved 14 June 2010.
Jump up ^ Richard D. McAnulty, M. Michele Burnette (2006) Sex and sexuality, Volume 1, Greenwood Publishing Group, p.165
^ Jump up to: a b c Mais, Daniel D. (2008). Quick compendium of clinical pathology (2nd ed.). Chicago: ASCP Press. ISBN 0891895671.
Jump up ^ Häggström, Mikael; Richfield, David (2014). "Diagram of the pathways of human steroidogenesis". WikiJournal of Medicine. 1 (1). ISSN 2002-4436. doi:10.15347/wjm/2014.005.
Jump up ^ Kenneth A. Pass; Eurico Carmago Neto (2005). Update: Newborn Screening for Endocrinopathies (PDF). pp. 831–834. Retrieved 12 Dec 2013.
Jump up ^ Meyer-Bahlburg, H. F. L.; Dolezal, C.; Haggerty, R.; Silverman, M.; New, M. I. (July 1, 2012). "Cognitive outcome of offspring from dexamethasone-treated pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency". European Journal of Endocrinology. 167 (1): 103–110. ISSN 0804-4643. PMC 3383400  . PMID 22549088. doi:10.1530/EJE-11-0789. Retrieved 2013-06-20.
Jump up ^ Elton, Catherine (2010-06-18). "A Prenatal Treatment Raises Questions of Medical Ethics". TIME. Retrieved 2010-07-05.
Jump up ^ Hirvikoski, Tatja; Nordenström, Anna; Wedell, Anna; Ritzén, Martin; Lajic, Svetlana (June 2012). "Prenatal Dexamethasone Treatment of Children at Risk for Congenital Adrenal Hyperplasia: The Swedish Experience and Standpoint". The Journal of Clinical Endocrinology & Metabolism. 97 (6): 1881–1883. ISSN 0021-972X. doi:10.1210/jc.2012-1222. Retrieved 2014-10-22.
Jump up ^ Dreger, Alice; Ellen K. Feder; Anne Tamar-Mattis (2010-06-29). "Preventing Homosexuality (and Uppity Women) in the Womb?". Bioethics Forum, a service of the Hastings Center. Retrieved 2010-07-05.
Jump up ^ Dreger, Alice; Feder, Ellen K.; Tamar-Mattis, Anne (September 2012). "Prenatal Dexamethasone for Congenital Adrenal Hyperplasia: An Ethics Canary in the Modern Medical Mine". Journal of Bioethical Inquiry. 9 (3): 277–294. ISSN 1872-4353. PMC 3416978  . PMID 22904609. doi:10.1007/s11673-012-9384-9. Retrieved 2014-10-22.
Jump up ^ Meyer-Bahlburg, Heino F.L. (1990). "Will Prenatal Hormone Treatment Prevent Homosexuality?". Journal of Child and Adolescent Psychopharmacology. 1 (4): 279–283. ISSN 1044-5463. doi:10.1089/cap.1990.1.279. Retrieved 2014-10-22.
Jump up ^ Dreger, Alice; Ellen K. Feder; Anne Tamar-Mattis (30 July 2012). "Prenatal Dexamethasone for Congenital Adrenal Hyperplasia". Journal of Bioethical Inquiry. 9 (3): 277–294. PMC 3416978  . PMID 22904609. doi:10.1007/s11673-012-9384-9.
Jump up ^ Fernández-Balsells, M.M.; K. Muthusamy; G. Smushkin; et al. (2010). "Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: A systematic review and meta-analyses". Clinical Endocrinology. 73 (4): 436–444. PMID 20550539. doi:10.1111/j.1365-2265.2010.03826.x.
Jump up ^ Bongiovanni, Alfred M.; Root, Allen W. (1963). "The Adrenogenital Syndrome". The New England Journal of Medicine. 268 (23): 1283. PMID 13968788. doi:10.1056/NEJM196306062682308.
Further reading[edit]
Han, Thang S.; Walker, Brian R.; Arlt, Wiebke; Ross, Richard J. (17 December 2013). "Treatment and health outcomes in adults with congenital adrenal hyperplasia". Nature Reviews Endocrinology. 10 (2): 115–124. PMID 24342885. doi:10.1038/nrendo.2013.239Figure 2: The adrenal steroidogenesis pathway.
External links[edit]
Wikimedia Commons has media related to Congenital adrenal hyperplasia.
Congenital adrenal hyperplasia at DMOZ
YourChild: Congenital Adrenal Hyperplasia University of Michigan Health System
Presentation by Gorsuch, AN. (8 July 2011) "Adrenal Disorders in Childhood & Adolescence"
International Fund raising Congenital Adrenal Hyperplasia: IFCAH
[show]
v
t
e
Diseases of the endocrine system (E00–E35, 240–259)
Pancreas/
glucose
metabolism
Hypofunction
Diabetes mellitus
types:
type 1
type 2
gestational
MODY 1 2 3 4 5 6
complications
coma
angiopathy
ketoacidosis
nephropathy
neuropathy
retinopathy
cardiomyopathy
insulin receptor (Rabson–Mendenhall syndrome)
Insulin resistance
Hyperfunction
Hypoglycemia
beta cell (Hyperinsulinism)
G cell (Zollinger–Ellison syndrome)
Hypothalamic/
pituitary axes
Hypothalamus
gonadotropin
Kallmann syndrome
Adiposogenital dystrophy
CRH (Tertiary adrenal insufficiency)
vasopressin (Neurogenic diabetes insipidus)
general (Hypothalamic hamartoma)
Pituitary
Hyperpituitarism
anterior
Acromegaly
Hyperprolactinaemia
Pituitary ACTH hypersecretion
posterior (SIADH)
general (Nelson's syndrome)
Hypopituitarism
anterior
Kallmann syndrome
Growth hormone deficiency
Hypoprolactinemia
ACTH deficiency/Secondary adrenal insufficiency
GnRH insensitivity
FSH insensitivity
LH/hCG insensitivity
posterior (Neurogenic diabetes insipidus)
general
Empty sella syndrome
Pituitary apoplexy
Sheehan's syndrome
Lymphocytic hypophysitis
Thyroid
Hypothyroidism
Iodine deficiency
Cretinism
Congenital hypothyroidism
Myxedema
Euthyroid sick syndrome
Hyperthyroidism
Hyperthyroxinemia
Thyroid hormone resistance
Familial dysalbuminemic hyperthyroxinemia
Hashitoxicosis
Thyrotoxicosis factitia
Graves' disease
Thyroiditis
Acute infectious
Subacute
De Quervain's
Subacute lymphocytic
Autoimmune/chronic
Hashimoto's
Postpartum
Riedel's
Goitre
Endemic goitre
Toxic nodular goitre
Toxic multinodular goiter
Thyroid nodule
Parathyroid
Hypoparathyroidism
Hypoparathyroidism
Pseudohypoparathyroidism
Pseudopseudohypoparathyroidism
Hyperparathyroidism
Primary
Secondary
Tertiary
Osteitis fibrosa cystica
Adrenal
Hyperfunction
aldosterone: Hyperaldosteronism/Primary aldosteronism
Conn syndrome
Bartter syndrome
Glucocorticoid remediable aldosteronism
AME
Liddle's syndrome
17α CAH
cortisol: Cushing's syndrome (Pseudo-Cushing's syndrome)
sex hormones: 21α CAH
11β CAH
Hypofunction/
Adrenal insufficiency
(Addison's, WF)
aldosterone: Hypoaldosteronism
21α CAH
11β CAH
cortisol: CAH
Lipoid
3β
11β
17α
21α
sex hormones: 17α CAH
Gonads
ovarian: Polycystic ovary syndrome
Premature ovarian failure
testicular: enzymatic
5α-reductase deficiency
17β-hydroxysteroid dehydrogenase deficiency
aromatase excess syndrome
Androgen receptor (Androgen insensitivity syndrome)
general: Hypogonadism (Delayed puberty)
Hypergonadism
Precocious puberty
Hypoandrogenism
Hypoestrogenism
Hyperandrogenism
Hyperestrogenism
Postorgasmic illness syndrome
Height
Dwarfism/Short stature
Midget
Laron syndrome
Psychosocial
Ateliosis
Gigantism
Multiple
Autoimmune polyendocrine syndrome multiple
APS1
APS2
Carcinoid syndrome
Multiple endocrine neoplasia
1
2A
2B
Progeria
Werner syndrome
Acrogeria
Metageria
Woodhouse–Sakati syndrome
[show]
v
t
e
Inborn errors of steroid metabolism
Mevalonate
pathway
HMG-CoA lyase deficiency
Hyper-IgD syndrome
Mevalonate kinase deficiency
To cholesterol
7-Dehydrocholesterol path: Hydrops-ectopic calcification-moth-eaten skeletal dysplasia
CHILD syndrome
Conradi-Hünermann syndrome
Lathosterolosis
Smith–Lemli–Opitz syndrome
desmosterol path: Desmosterolosis
Steroids
Corticosteroid
(including CAH)
aldosterone: Glucocorticoid remediable aldosteronism
cortisol/cortisone: CAH 17α-hydroxylase
CAH 11β-hydroxylase
both: CAH 3β-dehydrogenase
CAH 21-hydroxylase
Apparent mineralocorticoid excess syndrome/11β-dehydrogenase
Sex steroid
To androgens
17α-Hydroxylase deficiency
17,20-Lyase deficiency
3β-Hydroxysteroid dehydrogenase deficiency
17β-Hydroxysteroid dehydrogenase deficiency
5α-Reductase deficiency
Pseudovaginal perineoscrotal hypospadias
To estrogens
Aromatase deficiency
Aromatase excess syndrome
Other
X-linked ichthyosis
Antley–Bixler syndrome
Retrieved from "https://en.wikipedia.org/w/index.php?title=Congenital_adrenal_hyperplasia&oldid=804543666"
Categories:
Pediatrics
Adrenal gland disorders
Endocrine-related cutaneous conditions
Autosomal recessive disorders
Intersex and medicine
Hidden categories:
All articles with unsourced statements
Articles with unsourced statements from October 2016
Articles needing additional references from October 2015
All articles needing additional references
Articles with unsourced statements from October 2011
Articles with DMOZ links
Use dmy dates from July 2011
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
العربية
Català
Deutsch
ދިވެހިބަސް
Español
Euskara
فارسی
Français
한국어
Italiano
עברית
Nederlands
日本語
Oʻzbekcha/ўзбекча
Polski
Português
Română
Русский
Српски / srpski
Suomi
Svenska
தமிழ்
Українська
中文
Edit links
This page was last edited on 9 October 2017, at 18:07.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view

key: html

type: local

value: div

attrs: id class

values: mw-page-base noprint

values: mw-head-base noprint

attrs: id class style

value: a

attrs: id class lang

values: firstHeading firstHeading en

values: siteSub noprint

values: jump-to-nav mw-jump

attrs: href title

attrs: role class

values:
note
hatnote navigation-not-searchable

value: th

attrs: colspan style

value: tr

value: td

values: International Statistical Classification of Diseases and Related Health Problems

values:
nofollow
external text
https://omim.org/entry/201910

values:
nofollow
external text
https://omim.org/entry/201710

values:
nofollow
external text
https://omim.org/entry/202110

values:
nofollow
external text
https://omim.org/entry/201810

values:
nofollow
external text
https://omim.org/entry/202010

values:
/wiki/Primary_sex_characteristic
mw-redirect
Primary sex characteristic

values:
/wiki/Ambiguous_genitalia
mw-redirect
Ambiguous genitalia

values:
/wiki/Sexual_infantilism
mw-redirect
Sexual infantilism

values: This claim needs references to reliable sources. (October 2016)

values:
noprint Inline-Template Template-Fact
white-space:nowrap;

values: Help:Introduction to referencing with Wiki Markup/1

values: plainlinks metadata ambox ambox-content ambox-Refimprove

values:
/wiki/Polycystic_ovarian_syndrome
mw-redirect
Polycystic ovarian syndrome

attrs: alt src width height class srcset data-file-width data-file-height

values:
/wiki/3%CE%B2HSD_II
mw-redirect
3βHSD II

values:
/wiki/Cytochrome_P450_oxidase
mw-redirect
Cytochrome P450 oxidase

values:
/wiki/Positive_predictive_value
mw-redirect
Positive predictive value

values:
/wiki/Bone_maturation
mw-redirect
Bone maturation

values:
/wiki/Hastings_Center
mw-redirect
Hastings Center

values: This claim needs references to reliable sources. (October 2011)

values:
/wiki/Yupik_peoples
mw-redirect
Yupik peoples

values:
/wiki/Johns_Hopkins_Medical_School
mw-redirect
Johns Hopkins Medical School

values:
nofollow
external text
//www.worldcat.org/issn/2002-4436

values:
nofollow
external text
//doi.org/10.15347%2Fwjm%2F2014.005

values:
nofollow
external text
//www.worldcat.org/issn/0804-4643

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22549088

values:
nofollow
external text
//doi.org/10.1530%2FEJE-11-0789

values:
nofollow
external text
//www.worldcat.org/issn/0021-972X

values:
nofollow
external text
//doi.org/10.1210%2Fjc.2012-1222

values:
nofollow
external text
//www.worldcat.org/issn/1872-4353

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22904609

values:
nofollow
external text
//www.worldcat.org/issn/1044-5463

values:
nofollow
external text
//doi.org/10.1089%2Fcap.1990.1.279

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20550539

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/13968788

values:
nofollow
external text
//doi.org/10.1056%2FNEJM196306062682308

values: -moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24342885

values:
nofollow
external text
//doi.org/10.1038%2Fnrendo.2013.239

values:
nofollow
https://ifcahen.wordpress.com/
external text

values: ICD-10 Chapter IV: Endocrine, nutritional and metabolic diseases

values: List of ICD-9 codes 240–279: endocrine, nutritional and metabolic diseases, and immunity disorders

values:
/wiki/Glucose_metabolism_disorder
mw-redirect
Glucose metabolism disorder

values:
/wiki/Neurogenic_diabetes_insipidus
mw-redirect
Neurogenic diabetes insipidus

values:
/wiki/Hypothalamic_hamartoma
mw-redirect
Hypothalamic hamartoma

values: Syndrome of inappropriate antidiuretic hormone

values:
/wiki/Luteinizing_hormone_insensitivity
mw-redirect
Luteinizing hormone insensitivity

values:
/wiki/Lymphocytic_hypophysitis
mw-redirect
Lymphocytic hypophysitis

values:
/wiki/Toxic_nodular_goitre
mw-redirect
Toxic nodular goitre

values:
/wiki/Toxic_multinodular_goiter
mw-redirect
Toxic multinodular goiter

values:
/wiki/Conn_syndrome
mw-redirect
Conn syndrome

values: Apparent mineralocorticoid excess syndrome

values:
/wiki/Sex_hormone
mw-redirect
Sex hormone

values: Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

values:
/wiki/Waterhouse-Friderichsen_syndrome
mw-redirect
Waterhouse-Friderichsen syndrome

values:
/wiki/Gonadal_disorder
mw-redirect
Gonadal disorder

values:
/wiki/5%CE%B1-reductase_deficiency
mw-redirect
5α-reductase deficiency

values: Autoimmune polyendocrine syndrome multiple (page does not exist)

values: Autoimmune polyendocrine syndrome type 1

values: Autoimmune polyendocrine syndrome type 2

values: nowraplinks collapsible collapsed navbox-inner

values: Template:Defects of cholesterol and steroid metabolism

values: Template talk:Defects of cholesterol and steroid metabolism

values: Congenital adrenal hyperplasia due to 17α-hydroxylase deficiency

values: Congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase deficiency

values: nowraplinks collapsible autocollapse navbox-inner

values: Category:All articles with unsourced statements

values: Category:Articles with unsourced statements from October 2016

values: Category:Articles needing additional references from October 2015

values: Category:All articles needing additional references

values: Category:Articles with unsourced statements from October 2011

values: Discussion about edits from this IP address [ctrl-alt-n]

values: A list of edits made from this IP address [ctrl-alt-y]

values: You are encouraged to create an account and log in; however, it is not mandatory

values: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

values:
/wiki/Congenital_adrenal_hyperplasia
View the content page [ctrl-alt-c]
c

values: Discussion about the content page [ctrl-alt-t]

values: p-namespaces navigation vectorTabs p-namespaces-label

values:
p-variants
navigation
vectorMenu emptyPortlet
p-variants-label

values: Past revisions of this page [ctrl-alt-h]

values: p-views navigation vectorTabs p-views-label

values:
p-cactions
navigation
vectorMenu emptyPortlet
p-cactions-label

values:
mw-wiki-logo
/wiki/Main_Page
Visit the main page

values:
/wiki/Main_Page
Visit the main page [ctrl-alt-z]
z

values: Featured content – the best of Wikipedia

values: Find background information on current events

values:
/wiki/Special:Random
Load a random article [ctrl-alt-x]
x

values: portal navigation p-navigation p-navigation-label

values: Guidance on how to use and edit Wikipedia

values: About the project, what you can do, where to find things

values: A list of recent changes in the wiki [ctrl-alt-r]

values: portal navigation p-interaction p-interaction-label

values: List of all English Wikipedia pages containing links to this page [ctrl-alt-j]

values: Recent changes in pages linked from this page [ctrl-alt-k]

values: portal navigation p-wikibase-otherprojects p-wikibase-otherprojects-label

values: فرط تنسج الكظرية الخلقي – Arabic

values: Hiperplàsia suprarenal congènita – Catalan

values: އެޑްރީނޯޖެނިޓަލް ސިންޑްރޯމް – Divehi

values: Hiperplasia suprarrenal congénita – Spanish

values: هیپرپلازی مادرزادی آدرنال – Persian

values: Hyperplasie congénitale des surrénales – French

values: 선천부신과다형성 – Korean

values: Iperplasia surrenale congenita – Italian

values: היפרפלזיה מולדת של האדרנל – Hebrew

values: 先天性副腎過形成症 – Japanese

values: Hiperplasia adrenal congênita – Portuguese

values: Врождённая гиперплазия коры надпочечников – Russian

values: Kongenitalna adrenalna hiperplazija – Serbian

values: அட்ரீனல் கோளாறு – Tamil

values: Адреногенітальний синдром – Ukrainian

values: 先天性腎上腺增生症 – Chinese

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Congenital_adrenal_hyperplasia rootpage-Congenital_adrenal_hyperplasia vector-nav-directionality skin-vector action-view